businesspress24.com - Cleveland BioLabs to Report Third Quarter 2014 Financial Results and Provide Operational Update on N
 

Cleveland BioLabs to Report Third Quarter 2014 Financial Results and Provide Operational Update on November 5

ID: 1313249

(firmenpresse) - BUFFALO, NY -- (Marketwired) -- 10/28/14 -- (NASDAQ: CBLI) today announced that on November 5, 2014, it will report its financial results for the third quarter ended September 30, 2014, and will host a conference call at 10:00 a.m. ET.

Interested parties may participate by dialing 877-407-9205 (US) or 201-689-8054 (International), approximately five to ten minutes before the call start time. A live webcast of the conference call will be available on the investor page of the Cleveland BioLabs web site at .

A replay of the call will be available starting on November 5, 2014, at 1:00 p.m. ET through November 19, 2014, at 11:59 p.m. ET. Interested parties may access the replay by dialing 877-660-6853 (US) or 201-612-7415 (International) and entering conference ID number 13593933. An archived webcast of the conference call will be available for 90 days on the Investors page of the Cleveland BioLabs web site at .

Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company''s lead product candidates are Entolimod, which is being developed as radiation countermeasure and a potential cancer treatment, and Curaxin CBL0137, our lead oncology product candidate. The company conducts business in the United States and in the Russian Federation through our three operating subsidiaries, Incuron, LLC, BioLabs 612, LLC and Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children''s Cancer Institute Australia. To learn more about Cleveland BioLabs, Inc., please visit the Company''s website at .



Contact:
Rachel Levine
Vice President Investor Relations
Cleveland BioLabs, Inc.
T: (917) 375-2935
E:




Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Corbus Pharmaceuticals Commences Trading on OTCQB under Ticker Symbol CRBP
Regen BioPharma''s Chief Scientific Officer Examines Potential Role of Immunotherapeutic Treatment for Ebola in Conjunction With Other Current Therapies
Bereitgestellt von Benutzer: Marketwired
Datum: 28.10.2014 - 07:00 Uhr
Sprache: Deutsch
News-ID 1313249
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

BUFFALO, NY


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 170 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Cleveland BioLabs to Report Third Quarter 2014 Financial Results and Provide Operational Update on November 5
"
steht unter der journalistisch-redaktionellen Verantwortung von

Cleveland BioLabs, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Cleveland BioLabs, Inc.



 

Who is online

All members: 10 565
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 69


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.